CoChat

Effects of the Carnitine-acyltransferase Inhibitor Etomoxir on Insulin Sensitivity, Energy Expenditure and Substrate Oxidation in NIDDM

Hübinger, A., Knode, O., Susanto, F., Reinauer, H., Gries, F. · 1997 · Hormone and Metabolic Research

The DOI matches its Crossref record.

Abstract

We studied the influence of Etomoxir on fat and carbohydrate oxidation, and the influence of these changes on insulin sensitivity in type 2 diabetic patients. Etomoxir is an oxirane carboxylic acid derivative that specifically inactivates carnitine-acyltransferase I (CAT I, EC: 2.3.1.21), the key enzyme for the transport of long-chain acyl-CoA compounds into the mitochondria. Thus, oxidation of fatty acids should be reduced by this drug and glucose utilisation be increased according to the Randle mechanism. In order to test this hypothesis, we measured oxidative and non-oxidative glucose utilisation using the euglycaemic hyperinsulinaemic clamp technique, the isotope dilution mass spectrometry (IDMS) method with stable isotopes (6,6-D2-glucose) and indirect calorimetry. The clamps lasted 5 hours, indirect calorimetry was performed during the last hour and calculations of glucose disposal were based on steady state conditions during the last 30 minutes. Twelve type 2 diabetic patients were treated with 100 mg etomoxir/per day for 3 days in this placebo-controlled, randomized, double-blind study. Treatment resulted in a significant increase in carbohydrate oxidation (from 72 to 113 g/24 h, p = 0.039), decrease in fat oxidation (from 139 to 114 g/24 h, p = 0.037), and decrease of the glucose appearance rate (RA) in the basal state (from 1.85 to 1.70 mg/kg min., p = 0.014). During the euglycaemic clamp neither RA (3.30 and 3.20 mg/kg min., p = 0.471) nor the glucose infusion rate (4.28 and 4.53 mg/kg min., p = 0.125) showed significant changes. In addition, no significant changes in glucose and fat oxidation were detected during the hyperinsulinaemic clamp. Under basal conditions non-oxidative glucose utilisation was decreased by etomoxir (1.26 and 0.80 mg/ kg x min). Thus, we could demonstrate a decrease in fat and increase in glucose oxidation by etomoxir, but non-oxidative glucose utilisation was decreased. No significant changes could be demonstrated under clamp conditions.

Overview

Integrity signals

Registry

Crossref · 10.1055/s-2007-979072

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 39

Metadata

Authors
Hübinger, A., Knode, O., Susanto, F., Reinauer, H., & Gries, F.
Venue
Hormone and Metabolic Research
Published
1997-09
Volume
29
Issue
09
Pages
436-439
ISSN
  • 0018-5043 (ISSN-L)
  • 1439-4286
OpenAlex
W1995483958
Cited by
38
References
0
Citations by year
2025: 3 · 2020: 2 · 2019: 3 · 2018: 1 · 2016: 1 · 2015: 1 · 2014: 2 · 2013: 1 · 2012: 6
FWCI
0.71
Type
journal article
Language
en
Open access
closed
Locations
  • Hormone and Metabolic Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
etomoxir, type 2 diabetes, insulin sensitivity, glucose oxidation, fat oxidation, substrate oxidation, Randle cycle, energy expenditure, glucose appearance rate, hyperinsulinemic-euglycemic clamp, euglycaemic clamp, isotope dilution mass spectrometry
MeSH terms
Adult, Aged, Blood Glucose, Carnitine O-Acetyltransferase, Diabetes Mellitus, Type 2, Double-Blind Method, Energy Metabolism, Enzyme Inhibitors, Female, Humans, Insulin, Insulin Resistance, Kinetics, Male, Middle Aged, Oxidation-Reduction, Placebos, Glucose Clamp Technique

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of the Carnitine-acyltransferase Inhibitor Etomoxir on Insulin Sensitivity, Energy Expenditure and Substrate Oxidation in NIDDM. https://app.cochat.ai/papers/10.1055/s-2007-979072
The paper
Hübinger, A., Knode, O., Susanto, F., Reinauer, H., & Gries, F. (1997). Effects of the Carnitine-acyltransferase Inhibitor Etomoxir on Insulin Sensitivity, Energy Expenditure and Substrate Oxidation in NIDDM. Hormone and Metabolic Research. https://doi.org/10.1055/s-2007-979072

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.